Evidence map›Paper›PMID 25430652›Full record

ArticleRetrovirology2014

Characterization of HIV-1 envelopes in acutely and chronically infected injection drug users.

Behzad Etemad, Oscar A Gonzalez, Laura White, Oliver Laeyendecker, Gregory D Kirk, Shruti Mehta, Manish Sagar

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Virus-Host Gene Interactions Define HIV-1 Disease Progression.Current topics in microbiology and immunology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Behzad EtemadBoston University School of Medicine, Boston, MA, USA. betemad@bu.edu.
Oscar A GonzalezBoston University School of Medicine, Boston, MA, USA. oagonzal@bu.edu.
Laura WhiteBoston University School of Public Health, Boston, MA, USA. lfwhite@bu.edu.
Oliver LaeyendeckerJohns Hopkins University School of Medicine, Baltimore, MD, USA. olaeyen1@jhmi.edu.
Gregory D KirkJohns Hopkins University School of Medicine, Baltimore, MD, USA. gkirk@jhsph.edu.
Shruti MehtaJohns Hopkins University School of Medicine, Baltimore, MD, USA. shmehta@jhsph.edu.
Manish SagarBoston University School of Medicine, Boston, MA, USA. msagar@bu.edu.
Johns Hopkins Medicine · USBoston University · USJohns Hopkins University · US

Funding

The AIDS Linked to the Intravenous Experience (ALIVE) StudyU01DA036297 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Gregory D Kirk, Shruti H Mehta · 2014 to 2026
$28.9M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
INCIDENCE OF HIV INFECTIONS IN A COHORT OF IV DRUG USERSR01DA012568 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MEHTA, SHRUTI H · 1999 to 2017
$15.5M
Genotypic and Phenotypic Characterization of Heterosexually Transmitted HIV-1R01AI077473 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI SAGAR, MANISH · 2008 to 2011
$1.4M
Neutralizing and non-neutralizing antibodies protection from breast milk HIV-1R21AI102774 · NIAID · BOSTON MEDICAL CENTER · PI SAGAR, MANISH · 2012 to 2013
$452k
NIAID NIH HHS AI077473NIAID NIH HHS AI102774NIAID NIH HHS R01 AI077473NIAID NIH HHS R21 AI102774NIDA NIH HHS R01 DA012568NIDA NIH HHS U01 DA036297
6 · The paper itself

Abstract

backgroundMucosally acquired human immunodeficiency virus type 1 (HIV-1) infection results from a limited number of variants, and these infecting strains potentially have unique properties, such as increased susceptibility to entry blockers, relative interferon-alpha (IFN-α) resistance, and replication differences in some primary cells. There is no data about the phenotypic properties of HIV-1 envelope variants found early after acquisition among subjects infected through injection drug use (IDU). For the first time, we compared the characteristics of virus envelopes among injection drug users sampled prior to seroconversion (HIV RNA+/Ab-), within 1 year (early), and more than 2 years (chronic) after estimated acquisition.

resultsVirus envelopes from 7 HIV RNA+/Ab- subjects possessed lower genetic diversity and divergence compared to 7 unrelated individuals sampled during the chronic phase of disease. Replication competent recombinant viruses incorporating the HIV RNA+/Ab- as compared to the chronic phase envelopes were significantly more sensitive to a CCR5 receptor inhibitor and IFN-α and showed a statistical trend toward greater sensitivity to a fusion blocker. The early as compared to chronic infection envelopes also demonstrated a statistical trend or significantly greater sensitivity to CCR5 and fusion inhibitor and IFN- α. The HIV RNA+/Ab- as compared to chronic envelope viruses replicated to a lower extent in mature monocyte derived dendritic cells - CD4+ T cell co-cultures, but there were no significant replication differences in other primary cells among the viruses with envelopes from the 3 different stages of infection.

conclusionsSimilar to mucosal acquisition, HIV-1 envelope quasispecies present in injection drug users prior to seroconversion have unique phenotypic properties compared to those circulating during the chronic phase of disease.

Indexed as

Genetic VariationAntiviral AgentsCohort StudiesDrug Resistance, Viralenv Gene Products, Human Immunodeficiency VirusHIV-1HIV InfectionsHumansMolecular Sequence DataMutation, MissenseRNA, ViralSequence Analysis, DNASubstance Abuse, IntravenousVirulenceVirus ReplicationAntiviral Agentsenv Gene Products, Human Immunodeficiency VirusRNA, Viral

Identifiers

PMID25430652
PMCPMC4253609
OpenAlexW2160537812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.